Compare Stocks → Biden replacement revealed? (From Paradigm Press) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:AVEONASDAQ:ICPTNASDAQ:LXRXNASDAQ:XOMA Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAVEOAVEO Pharmaceuticals$15.00$14.97$3.06▼$15.00$521.45M1601,442 shs247,800 shsICPTIntercept Pharmaceuticals$19.00$18.88$8.82▼$21.86$794.77M0.881.36 million shsN/ALXRXLexicon Pharmaceuticals$1.60-0.6%$2.31$0.92▼$3.79$393.98M1.274.41 million shs1.76 million shsXOMAXOMA$25.64-1.7%$24.69$13.48▼$27.00$298.45M0.5821,031 shs8,219 shsThese 7 Stocks Will Be Magnificent in 2024With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAVEOAVEO Pharmaceuticals0.00%0.00%0.00%0.00%0.00%ICPTIntercept Pharmaceuticals0.00%0.00%0.00%0.00%+0.21%LXRXLexicon Pharmaceuticals-5.85%-5.01%-28.76%-6.94%-32.07%XOMAXOMA+1.05%+7.01%+5.20%+27.58%+43.67%Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS (Ad)You might have seen that Bitcoin was one of the best performing assets of 2023. It gained 164%. But a crypto millionaire who has been tracking the space for more than a decade has ABANDONED Bitcoin. He found something better.Click here to find out that this 8,788% cryptocurrency is.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAVEOAVEO PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AICPTIntercept Pharmaceuticals0.3046 of 5 stars1.00.00.03.90.01.70.6LXRXLexicon Pharmaceuticals0.9598 of 5 stars3.01.00.00.01.71.70.6XOMAXOMA3.6343 of 5 stars3.52.00.03.02.41.70.6Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAVEOAVEO PharmaceuticalsN/AN/AN/AN/AICPTIntercept Pharmaceuticals2.00Hold$19.864.51% UpsideLXRXLexicon Pharmaceuticals2.00Hold$5.00212.50% UpsideXOMAXOMA3.00Buy$74.00188.61% UpsideCurrent Analyst RatingsLatest LXRX, AVEO, XOMA, and ICPT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/23/2024LXRXLexicon PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingHold4/11/2024LXRXLexicon PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingHold2/16/2024XOMAXOMAHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$74.00(Data available from 4/24/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAVEOAVEO Pharmaceuticals$42.29M12.33N/AN/A$1.33 per share11.28ICPTIntercept Pharmaceuticals$285.71M2.78N/AN/A$1.72 per share11.05LXRXLexicon Pharmaceuticals$1.20M328.32N/AN/A$0.38 per share4.21XOMAXOMA$4.76M62.70N/AN/A$7.72 per share3.32Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAVEOAVEO Pharmaceuticals-$53.34M-$0.84N/A28.85N/A-30.79%-81.66%-28.83%N/AICPTIntercept Pharmaceuticals$221.82M-$1.48N/A9.84N/A-19.39%-77.48%-11.99%N/ALXRXLexicon Pharmaceuticals-$177.12M-$0.80N/AN/AN/A-14,573.20%-138.54%-71.29%5/7/2024 (Estimated)XOMAXOMA-$40.83M-$4.04N/AN/AN/A-886.91%-25.17%-17.08%5/14/2024 (Estimated)Latest LXRX, AVEO, XOMA, and ICPT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/11/2024Q4 2023LXRXLexicon Pharmaceuticals-$0.23-$0.20+$0.03-$0.20$0.68 million$0.70 million3/8/2024Q4 2023XOMAXOMA-$0.36-$0.49-$0.13$0.89$1.01 million$1.83 millionDividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAVEOAVEO PharmaceuticalsN/AN/AN/AN/AN/AICPTIntercept PharmaceuticalsN/AN/AN/AN/AN/ALXRXLexicon PharmaceuticalsN/AN/AN/AN/AN/AXOMAXOMAN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAVEOAVEO Pharmaceuticals0.942.372.35ICPTIntercept Pharmaceuticals3.124.222.52LXRXLexicon Pharmaceuticals1.075.605.58XOMAXOMA1.348.688.68OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAVEOAVEO Pharmaceuticals49.95%ICPTIntercept Pharmaceuticals83.81%LXRXLexicon Pharmaceuticals74.70%XOMAXOMA95.92%Insider OwnershipCompanyInsider OwnershipAVEOAVEO Pharmaceuticals3.29%ICPTIntercept Pharmaceuticals6.20%LXRXLexicon Pharmaceuticals4.50%XOMAXOMA7.20%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableAVEOAVEO Pharmaceuticals11434.76 million33.62 millionOptionableICPTIntercept Pharmaceuticals34141.83 million39.19 millionOptionableLXRXLexicon Pharmaceuticals285246.24 million235.16 millionOptionableXOMAXOMA1311.64 million10.80 millionOptionableLXRX, AVEO, XOMA, and ICPT HeadlinesSourceHeadlineActym Therapeutics Appoints Thomas Smart as CEOprnewswire.com - April 24 at 9:00 AMXOMA (NASDAQ:XOMA) shareholders have earned a 16% CAGR over the last five yearsfinance.yahoo.com - April 20 at 9:43 AMXOMA (NASDAQ:XOMA) Share Price Passes Above Two Hundred Day Moving Average of $19.93americanbankingnews.com - April 17 at 2:58 AMXOMA Co. (NASDAQ:XOMA) Shares Sold by Stonepine Capital Management LLCmarketbeat.com - April 9 at 9:43 PMXOMA Corporation Announces Closing of Tender Offerglobenewswire.com - April 3 at 9:00 AMXOMA Declares Quarterly Preferred Stock Dividendsglobenewswire.com - March 21 at 7:30 AMXOMA Announces Calculation of Additional Price Per Share and Extension of Expiration Date for Tender Offer for Kinnate Biopharma Inc.globenewswire.com - March 19 at 4:05 PMKINNATE BIOPHARMA INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Kinnate Biopharma Inc. - KNTEbusinesswire.com - March 13 at 11:49 AMXOMA Stock Earnings: XOMA Misses EPS, Misses Revenue for Q4 2023investorplace.com - March 8 at 1:03 PMXOMA Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent and Upcoming Events Expected to Drive Shareholder Valuefinance.yahoo.com - March 8 at 7:51 AMXOMA Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent and Upcoming Events Expected to Drive Shareholder Valueglobenewswire.com - March 8 at 7:30 AMXOMA to Present at Upcoming Investor Conferences in Marchglobenewswire.com - February 28 at 7:30 AMKINNATE BIOPHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Kinnate Biopharma Inc. - KNTEbusinesswire.com - February 19 at 11:03 AMCompare with Maple Leaf Green World Inc (4HV0)msn.com - February 18 at 12:30 PMXOMA to acquire Kinnate Biopharmathepharmaletter.com - February 17 at 10:21 AMXOMA Mar 2024 20.000 putfinance.yahoo.com - February 17 at 10:21 AMXOMA Jun 2024 25.000 callfinance.yahoo.com - February 17 at 10:21 AMBiotech Royalty Aggregator XOMA To Acquire Small Cancer-Drug Developer Kinnate Biopharmabenzinga.com - February 16 at 1:37 PMXOMA Agrees to Acquire Kinnate Biopharmamarketwatch.com - February 16 at 8:36 AMXOMA Enters into Agreement to Acquire Kinnate Biopharma for Between $2.3352 and $2.5879 in Cash Per Share Plus a Contingent Value Rightfinance.yahoo.com - February 16 at 8:36 AMXOMA Enters into Agreement to Acquire Kinnate Biopharma for Between $2.3352 and $2.5879 in Cash Per Share Plus a Contingent Value Rightfinance.yahoo.com - February 16 at 8:36 AMXOMA Enters into Agreement to Acquire Kinnate Biopharma for Between $2.3352 and $2.5879 in Cash Per Share Plus a Contingent Value Rightglobenewswire.com - February 16 at 8:00 AMWith 37% ownership, XOMA Corporation (NASDAQ:XOMA) has piqued the interest of institutional investorsfinance.yahoo.com - January 20 at 2:06 PMXOMA To Pay $1 Mln Milestone To LadRx As FDA Accepts Zevra's Arimoclomol NDA For NPCmarkets.businessinsider.com - January 11 at 10:48 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsAVEO PharmaceuticalsNASDAQ:AVEOAVEO Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the advancement of therapeutics for oncology, and other areas of unmet medical need. Its product candidates include Tivozanib, Ficlatuzmab, AV-203, AV-380 and AV-353. The company was founded by Ronald A. DePinho, Lynda Chin, and Kenneth E. Weg on October 19, 2001 and is headquartered in Cambridge, MA.Intercept PharmaceuticalsNASDAQ:ICPTIntercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. The company markets Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis in combination with ursodeoxycholic acid in adults. It is also developing Ocaliva for various indications, including nonalcoholic steatohepatitis and NASH; and other product candidates in various stages of clinical and preclinical development. The company has a license agreement with Aralez Pharmaceuticals Canada Inc. to develop and commercialize bezafibrate in the United States. It markets its products through an internal commercial organization and third-party distributors. The company was incorporated in 2002 and is headquartered in Morristown, New Jersey. As of November 8, 2023, Intercept Pharmaceuticals, Inc. operates as a subsidiary of Alfasigma S.p.A..Lexicon PharmaceuticalsNASDAQ:LXRXLexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract. Lexicon Pharmaceuticals, Inc. has strategic collaboration and license agreements with Bristol-Myers Squibb Company and Genentech, Inc. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.XOMANASDAQ:XOMAXOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets. It has a portfolio with various assets. XOMA Corporation was incorporated in 1981 and is headquartered in Emeryville, California. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.